Nouscom
  • Home
  • About
  • Technology
  • Pipeline
  • Investors
  • News
    • Grants
    • External presentations
    • Press Releases
    • Scientific publications
    • Conferences
  • Contact
Next-generation treatment for cancer Next-generation treatment for cancer Next-generation treatment for cancer Next-generation treatment for cancer
  • Home
  • About
  • Technology
  • Pipeline
  • Investors
  • News
    • Grants
    • External presentations
    • Press Releases
    • Scientific publications
    • Conferences
  • Contact

Scientific publications

Home » Scientific publications
0

Adenoviral-based vaccine promotes neoantigen-specific CD8 + T cell stemness and tumor rejection

D’Alise AM et al. Sci Transl Med 2022

READ MORE
0

VENUS, a Novel Selection Approach to Improve the Accuracy of Neoantigens’ Prediction

Leoni G, D’Alise AM et al. Vaccines 2021

READ MORE
0

A Genetic Vaccine Encoding Shared Cancer Neoantigens to Treat Tumors with Microsatellite Instability

Leoni G et al, Cancer Research, 2020

READ MORE
0

New viral vectors for infectious diseases and cancer

Sasso E, D’Alise AM et al. Semin Immunol. 2020

READ MORE
0

Adenoviral vaccine targeting multiple neoantigens as strategy to eradicate large tumors combined with checkpoint blockade

D’Alise AM et al., Nature Comms, 2019

READ MORE
0

Immune Profiling of Premalignant Lesions in Patients With Lynch Syndrome

Chang et al., JAMA Oncology, 2018 

READ MORE
Contact
  • NOUSCOM
  • info@nouscom.com
  • nouscom.com
Our Privacy

Privacy Policy & Cookie Low

Nouscom is a private oncology company developing next generation immunotherapies, founded in 2015 by an experienced management team that has worked together for many years in previous successful enterprises. Nouscom’s proprietary technology platform harnesses the full power of the immune response by combining viral vectored genetic vaccines based on neoantigens with other immunomodulators.

© Copyright 2018 | Made with by
error: Content is protected !!!